Vertex Pharmaceuticals financials
$526.73−0.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B | $4.16B | $3.05B | $2.49B | $1.70B |
| Gross profit | $10.35B | $9.49B | $8.61B | $7.85B | $6.67B | $5.47B | $3.62B | $2.64B | $2.21B | $1.49B |
| Gross margin | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% |
| Operating income | $4.17B | -$232.9M | $3.83B | $4.31B | $2.78B | $2.86B | $1.20B | $635.1M | $123.2M | $9.9M |
| Net income | $3.95B | -$535.6M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B | $2.10B | $263.5M | -$112.1M |
| Net margin | 32.9% | −4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | −6.6% |
| Diluted EPS | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | $-0.46 |
| EBITDA | $4.90B | $4.60B | $4.54B | $4.51B | $4.02B | $2.98B | $1.31B | $736.4M | $454.2M | $72.6M |
| Operating cash flow | $3.63B | -$492.6M | $3.54B | $4.13B | $2.64B | $3.24B | $1.56B | $1.27B | $684.9M | $236.1M |
| Free cash flow | $3.19B | -$790.3M | $3.34B | $3.93B | $2.41B | $2.98B | $1.49B | $1.17B | $585.5M | $179.5M |
| Diluted shares | 258.0M | 257.9M | 260.5M | 259.1M | 259.9M | 263.4M | 260.7M | 259.2M | 253.2M | 244.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.08B | $4.57B | $10.37B | $10.50B | $6.79B | $5.99B |
| Short-term investments | $1.52B | $1.55B | $849.2M | $274.5M | $729.9M | $670.7M |
| Total debt | $0.00 | $0.00 | $376.1M | $430.8M | $509.8M | $539.0M |
| Total assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B | $11.75B |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B | $3.06B |
| Shareholders' equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B | $8.69B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology